Meiby Rodríguez-González

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva et al. · The Lancet Regional Health - Americas · 2022 · 44 citations · Full text

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González et al. · Vaccine · 2022 · 38 citations · Full text

Vaccination, Vaccine Safety, Open Label Phase +6

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva et al. · 2021 · 31 citations · Full text

Immunodeficiencies, Immunology, Immunodominance +20

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

Sonia Pérez-Rodríguez, Meiby Rodríguez-González, Rolando Ochoa-Azze et al. · Vaccine · 2022 · 31 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte et al. · International Journal of Infectious Diseases · 2022 · 21 citations · Full text